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Abstract
Disclosing secondary findings (SF) from genome sequencing (GS) can alert carriers to disease risk. However, evidence
around variant-disease association and consequences of disclosure for individuals and healthcare services is limited. We
report on the feasibility of an approach to identification of SF in inherited cardiac conditions (ICC) genes in participants in a
rare disease GS study, followed by targeted clinical evaluation. Qualitative methods were used to explore behavioural and
psychosocial consequences of disclosure. ICC genes were analysed in genome sequence data from 7203 research
participants; a two-stage approach was used to recruit genotype-blind variant carriers and matched controls. Cardiac-focused
medical and family history collection and genetic counselling were followed by standard clinical tests, blinded to genotype.
Pathogenic ICC variants were identified in 0.61% of individuals; 20 were eligible for the present study. Four variant carriers
and seven non-carrier controls participated. One variant carrier had a family history of ICC and was clinically affected; a
second was clinically unaffected and had no relevant family history. One variant, in two unrelated participants, was
subsequently reclassified as being of uncertain significance. Analysis of qualitative data highlights participant satisfaction
with approach, willingness to follow clinical recommendations, but variable outcomes of relatives’ engagement with
healthcare services. In conclusion, when offered access to SF, many people choose not to pursue them. For others, disclosure
of ICC SF in a specialist setting is valued and of likely clinical utility, and can be expected to identify individuals with, and
without a phenotype.
Introduction
Genome sequencing (GS) has been widely adopted by
healthcare systems to investigate genomic contributions to
rare disease and cancer [1]. GS coincidentally creates large
amounts of data of potential health significance (secondary
findings, SF), that are or may be unrelated to the presenting
condition. SF are perceived both as an opportunity to pre-
dict and prevent disease [2] and a challenge to imple-
mentation of genomic medicine [3].
Inherited cardiac conditions (ICC) have a population
prevalence of up to one in 200; a proportion result from a
single variant in any one of a number of genes. ICC—which
include hypertrophic cardiomyopathy (HCM), dilated car-
diomyopathy (DCM), arrhythmogenic right ventricular
cardiomyopathy (ARVC), long QT syndrome and Brugada
syndrome—are often asymptomatic, yet pose a risk of
complications including sudden cardiac death. Disease
manifestation and risk of complications, including
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arrhythmogenic events, can be assessed using standard
cardiological tests based on imaging and ECG. Evidence-
based risk strategies to manage risk include medical and
lifestyle management, and cardiac defibrillator implantation
[4–6].
Policy around search and return of SF will be informed
by clinical actionability, including the positive predictive
value of SF in populations not ascertained for the associated
health condition. This question is more amenable to study in
ICC than some other disorders, since disease expression can
be assessed in any adult variant carrier through detailed
clinical assessment at the time of presentation. In the con-
text of manifest disease, family-based studies demonstrate
the incomplete and variable penetrance of ICC variants
[7–9]. While genotype-first approaches overcome the
ascertainment bias inherent to case series and family-based
studies, phenotypic features described are often derived
from retrospective electronic medical records, lack specific
ICC-targeted investigations, and hence may underestimate
the magnitude of any effect [10–14]. The few reports of ICC
SF disclosure highlight challenges with interpreting variants
and correlating them with clinical findings and family his-
tory, and with patient management [15–17]. Pathogenicity
assessment remains a challenge, especially in heterozygous
disorders caused by missense variants [18].
The majority of patients, public and healthcare profes-
sionals support the return of ‘actionable’ SF, however,
appreciation of the complexity of genomic information may
temper attitudes to the scope of findings [19]. Increasingly,
GS is expanding to ‘healthy’ cohorts; while recent initia-
tives have sought consent to return SF in variable gene lists,
earlier ones did not, posing dilemmas relating to ethical
recall-by-genotype studies [20].
Here we report on an approach to disclosure and targeted
clinical evaluation of ICC SF in an established rare disease
study cohort: a recall-by-genotype double blind, case-
control feasibility study which aimed to assess the pene-
trance of ICC gene variants in an unselected population, and
explore the psychosocial and behavioural sequelae of clin-
ical assessment. The study, Secondary Cardiac Findings
Evaluation (SCARFE), piloted a two-stage recruitment
approach, designed to disclose SF information in an expert
setting, and to enhance participant autonomy [21] in parti-
cipants who were not offered SF options at initial
recruitment.
Materials and methods
NIHR BioResource for rare disease (BRRD)
BRRD (https://bioresource.nihr.ac.uk/rare-diseases/rare-disea
ses/) enrolled affected participants and their relatives across
several different rare disease areas including infection and
immunity, neuroscience, rare cancers and cardiovascular
disease (Research Ethics Committee (REC) reference 13/EE/
0325). Consent to BRRD included recontact for additional
‘Stage 2’ studies. The SCARFE study was approved by
London Fulham research ethics committee (REC reference
17/LO/1579).
Genome sequencing
GS of DNA from blood samples from BRRD participants
was undertaken as reported elsewhere [22].
Genomic analysis and participant re-identification
Twenty ICC genes robustly associated with HCM (ACTC1,
GLA, LAMP2, MYL2, MYBPC3, MYL3, MYH7, TNNI3,
TNNT2, TPM1), DCM (LMNA, VCL, MYH7, TNNI3,
TNNT2, TPM1), ARVC (DSC2, DSG2, DSP, PKP2) and
long QT syndrome (KCNH2, KCNQ1, SCN5A) were eval-
uated (Table 1) in sequence data from BRRD participants
not known to have an ICC. Previously reported variants
classified pathogenic in the context of autosomal dominant
ICC (Oxford Medical Genetics Laboratory, OMGL; Part-
ners Laboratory of Molecular Medicine [23]; or ClinVar),
and truncating variants in genes where this class of variant
is considered pathogenic, were extracted. Variants assigned
pathogenic or likely pathogenic status were confirmed by
Sanger sequencing by the BRRD. The TTN gene was not
included since at the time of analysis, understanding of
variant-disease association was incomplete and variants not
considered actionable.
Codes of all participants harbouring a likely/highly
likely pathogenic variant, together with variant details,
were made available to the BRRD, who re-identified
participants and assessed for eligibility: age 18–80 years,
not known to have a condition associated with the SF, or
that might confound clinical test interpretation, and
matched with non-carrier controls by age, gender and
primary disease cohort. Inclusion of matched non-variant
carrier controls allowed us to approach BRRD partici-
pants without disclosing variant carrier status, to perform
and analyse targeted tests while blind to genotype and to
study impacts of the double blind approach on all
participants.
Participant approach
Eligible BRRD participants and controls were initially sent
an ‘opt-out’ letter [21] (Supplementary Material). Partici-
pants (cases and controls) who did not opt out within
4 weeks were sent an invitation letter to SCARFE
requesting reply to the BRRD team, using a code for the
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specific ICC associated with the variant. Contact details of
participants who responded positively were passed to the
SCARFE study team. Case/control status was blind to
participants and SCARFE study team.
Study visit
Study rationale, possible outcomes, clinical and lifestyle
consequences of significant clinical findings and presence
Table 1 Variants identified in genome sequence data: candidate gene variants considered ‘highly likely’ or ‘likely’ pathogenic.
Disease associated Gene Reference sequence c. p. No.
occurrences
Variant
classification
ARVC DSC2 NM_024422.3 c.1123C > T p.(Arg375*) 1 Pathogenic
ARVC DSC2 NM_024422.3 c.2533G > T (variant not
confirmed)
p.(Glu845*) 1 Likely pathogenic
ARVC DSC2 NM_024422.3 c.379G > T p.(Glu127*) 1 Likely pathogenic
ARVC DSC2 NM_024422.3 c.939_942delAGAG p.(Arg313fs) 1 Likely pathogenic
ARVC DSC2 NM_024422.3 c.959delA p.(Gln320fs) 1 Likely pathogenic
ARVC DSG2 NM_001943.4 c.1880-2 A > G p.? 1 Pathogenic
ARVC DSG2 NM_001943.4 c.2894_2897delAGAG p.(Glu965fs) 1 Likely pathogenic
ARVC DSG2 NM_001943.4 c.355C > T p.(Arg119*) 1 Likely pathogenic
ARVC DSG2 NM_001943.4 c.375dupT p.(Leu126fs) 2 Pathogenic
ARVC DSG2 NM_001943.4 c.603_604delAT p.(Leu203fs) 1 Likely pathogenic
ARVC PKP2 NM_004572.3 c.1035-1G > C p.? 1 Likely pathogenic
ARVC PKP2 NM_004572.3 c.1237C > T p.(Arg413*) 1 Pathogenic
ARVC PKP2 NM_004572.3 c.2146-1G > C p.? 1 Pathogenic
ARVC PKP2 NM_004572.3 c.2194C > T p.(Gln732*) 1 Pathogenic
ARVC PKP2 NM_004572.3 c.2378_2379dupCC p.(Ser794fs) 1 Pathogenic
ARVC PKP2 NM_004572.3 c.2478delT p.(Ser826fs) 1 Pathogenic
DCM LMNA NM_170707.3 c.949G > A p.(Glu317Lys) 1 Likely pathogenic
HCM GLA NM_000169.2 c.644A > G p.(Asn215Ser) 1 Pathogenic
HCM MYBPC3 NM_000256.3 c.1504C > T p.(Arg502Trp) 3 Pathogenic
HCM MYBPC3 NM_000256.3 c.1624G> C p.(Glu542Gln) 1 Pathogenic
HCM MYBPC3 NM_000256.3 c.2373dupG p.(Trp792fs) 1 Pathogenic
HCM MYBPC3 NM_000256.3 c.26-2A > G p.? 2 Likely pathogenic
HCM MYBPC3 NM_000256.3 c.3192dupC p.(Lys1065fs) 1 Pathogenic
HCM MYBPC3 NM_000256.3 c.3592dupG p.(Ala1198fs) 1 Pathogenic
HCM MYBPC3 NM_000256.3 c.772G > A p.(Glu258Lys) 2 Pathogenic
HCM MYBPC3 NM_000256.3 c.994G > T p.(Glu332*) 1 Pathogenic
HCM MYL3 NM_000258.2 c.170C > G p.(Ala57Gly) 2 Likely
pathogenic*
HCM MYH7 NM_000257.2 c.4066G > A p.(Glu1356Lys) 1 Likely pathogenic
HCM TNNI3 NM_000363.4 c.433C > T p.(Arg145Trp) 2 Pathogenic
HCM TNNI3 NM_000363.4 c.434G > A p.(Arg145Gln) 1 Likely pathogenic
HCM TNNI3 NM_000363.4 c.484C > T p.(Arg162Trp) 1 Likely
pathogenic*
HCM TNNI3 NM_000363.4 c.485G > A p.(Arg162Gln) 1 Likely
pathogenic*
LQTS KCNH2 NM_000238.3 c.1744C > T p.(Arg582Cys) 1 Likely pathogenic
LQTS KCNQ1 NM_000218.2 c.1066C > T p.(Gln356*) 2 Pathogenic
LQTS KCNQ1 NM_000218.2 c.1780C > T p.(Arg594*) 1 Pathogenic
LQTS KCNQ1 NM_000218.2 c.1781G > A p.(Arg594Gln) 1 Likely pathogenic
LQTS SCN5A NM_001099404.1 c.6017dupC p.(Ser2007fs) 1 Likely pathogenic
Total number of
participants
45
No. occurrences= number of times variant found in the BRRD cohort (n= 7203). Variants reviewed and classified January–March 2017.
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of an ICC gene variant for the participant and relatives,
were discussed in full with potential SCARFE participants
before written informed consent was taken. A cardiac-
focussed medical history and three-generation pedigree
were recorded. Clinical evaluation was performed by a
single experienced operator using the same equipment
according to the ICC associated with the variant detected.
Clinical tests were interpreted by a cardiologist specialised
in ICC and a diagnostic opinion recorded, prior to
unblinding of case/control status. All findings were dis-
closed to participants the same day, with letter to participant
general practitioner and recommendations regarding clinical
follow-up in a National Health Service ICC clinic, and
family cascade testing as appropriate, supported by family
cascade letters. Variants were re-confirmed in a fresh sam-
ple by OMGL prior to cascade testing.
Qualitative data collection and analysis
Semi-structured interviews were undertaken by the first
author between 6 and 12 months post visit using a guide
developed through clinical experience and literature review.
Interviews aimed to explore participant perceptions of being
approached and of the study visit, their reactions to the
information received, whom they had discussed the visit
with, and reasons for any lifestyle changes. Interviews were
audio recorded and verbatim transcripts analysed themati-
cally [24] by the first two authors.
Results
Genetic analysis
Pathogenic/likely pathogenic variants within ICC genes
were detected and confirmed in 44/7203 (0.61%) BRRD
participants: numbers of participants carrying a variant
associated with each disease: 16 ARVC, 1 DCM, 21 HCM,
6 LQTS (Table 1). Sanger sequencing failed to confirm one
variant in one BRRD participant, who was not invited to
SCARFE.
Participants
Twelve of the 44 variant carriers were ineligible and a fur-
ther 12 could not be contacted or were considered unsuitable
by the referring clinician. Initial opt-out letters were sent to
20 variant carriers, and returned by two. Invitation letters
were sent to the remaining 18 eligible variant carriers, of
whom 14 actively declined or did not respond to invitations.
Four (mean age= 60) eligible variant carriers attended a
study visit and participated. Approach and numbers at each
stage are shown in Fig. 1. Variants carried by all four were
in genes associated with HCM.
Seven non-carrier controls (mean age= 55) participated;
four were matched to a case who declined or did not
respond, and for one case, two controls were invited but
declined or did not respond. Ten participants who attended
a study visit took part in a semi-structured interview; one
did not respond to requests.
Clinical findings, family history and genotype
Genetic variants, demographic data and clinical findings of
variant carriers who attended for assessment are shown in
Table 2.
B3 is a 70-year-old asymptomatic woman. Study visit
echocardiogram showed septum measurement at the upper
limit of normal with normal left ventricular size and systolic
function, no left ventricular outflow tract obstruction, no
systolic anterior motion, normal atria and no voltage criteria
for left ventricular hypertrophy (LVH) on ECG. B3 has no
Fig. 1 SCARFE recruitment by
genotype process, showing the
numbers of BRRD participants
at each stage.
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known family history of HCM or sudden cardiac death.
Clinical verdict was that B3 was not affected with HCM.
After unblinding, B3 was found to carry a well-established
pathogenic HCM variant in MYBPC3 [25] and was referred
for clinical care: clinical cardiac magnetic resonance (CMR)
imaging confirmed absence of LVH. B3 has three living
adult first-degree relatives who have subsequently been
tested, of whom one has the variant and is clinically
unaffected.
B13 is a 46-year-old asymptomatic man employed in a
profession requiring medical certification. Genotype-blind
echocardiogram showed mild hypertrophy in the mid-
septum with normal left ventricular size and systolic func-
tion, no left ventricular outflow tract obstruction, no systolic
anterior motion and normal atria; ECG showed no criteria
for LVH. One sibling had a prior diagnosis of HCM; no
clinical genetic testing had been performed. Following the
sibling’s diagnosis, B13 was clinically screened in his 30s,
considered unaffected and discharged. Clinical verdict was
that B13 was affected with HCM. He was found to carry a
novel variant in MYBPC3 predicted to result in premature
termination of translation resulting in haploinsufficiency, a
known disease mechanism in HCM. Subsequent clinical
CMR confirmed asymmetric septal hypertrophy (MWT 1.8
cm) with large areas of patchy fibrosis with late gadolinium
enhancement. Twenty-four hours ECG and exercise test
were normal. Family testing is ongoing.
B20 is a 66-year-old asymptomatic woman with normal
left ventricular size and systolic function, no left ventricular
outflow tract obstruction, no systolic anterior motion, nor-
mal atria and normal ECG. Two first-degree relatives suf-
fered sudden deaths both at age 76. Clinical verdict was that
B20 was not affected with HCM. She was found to have a
variant in MYL3 considered likely pathogenic for HCM at
the time of SCARFE genomic analysis: this variant is
reported as pathogenic on ClinVar due to segregation and
functional work in vitro [26] and in vivo [27], but has a
higher than expected allele frequency (0.0072%) in gno-
mAD (r.2.1.1). After the study visit we reviewed the variant
and considered evidence for pathogenicity uncertain, with
further cardiac investigations not warranted. Cause of death
in relatives was certified as cardiac failure and hypertension
(parent); acute myocardial infarction, coronary athero-
sclerosis and myocardial hypertrophy and hypercholester-
olaemia (sibling). Cascade testing is ongoing.
B17 is a 61-year-old asymptomatic woman. She has
normal left ventricular size with normal wall dimensions
and function, no left ventricular outflow tract obstruction,
no systolic anterior motion and normal atria, normal ECG.
She has no family history of HCM or sudden death. Clinical
verdict was that B17 was not affected with HCM. B17
carries the same MYL3 variant detected in B20. Cascade
testing is ongoing.
Clinical data for the non-variant carriers are shown in
Table 3. None was considered to have clinical features
diagnostic of the ICC for which they had been enrolled as
controls.
Qualitative data analysis
Understanding of genetic health risks
Participants talked at length about the primary health con-
dition (for which participants were enrolled in the BRRD)
in them/their child, and the multiple psychosocial and
practical burdens it had imposed on the family. No parti-
cipant had yet received a genetic diagnosis. Experience with
the primary health condition had informed participants
about concepts such as inherited disease and risk, variable
penetrance and expressivity, and diseases for which treat-
ment is available but no cure. Some participants considered
that leading a healthy lifestyle could mitigate disease
development in general, despite presumed genetic risk. One
of the participants carrying a variant subsequently reclas-
sified already had experience of a variant of unknown sig-
nificance (VUS) found in relation to the primary condition;
she explained her understanding of the meaning of uncer-
tainty in genetic disease:
‘This unknown significant stuff, I’d had a lot of time
to get my head around with [child] having something,
which they had downplayed considerably. That’s
quite different from this unknown variation. I thought
it was a very binary answer. It was either, ‘Yes,’ or,
‘No,’ and because I knew that I hadn’t got any heart
problems, because my ECG had been fine and
everything else, then, I just assumed that I was a no.
It never occurred to me’. (B17).
Motivation for and satisfaction with participation in SCARFE
Participants agreed to take part for altruistic reasons as well
as personal and family reasons. Only two (of ten) partici-
pants recollected the two-stage SCARFE approach. Of
interest given the low response rate, one participant had
assumed that she was ‘one of many’, and that her partici-
pation was not critical. Although some participants reported
anxiety about the tests and what they might show, all were
satisfied with the study processes before, during and after
the study visit; they valued the ‘personalised approach’,
‘empathy’ and ‘clarity’, at the study visit, and availability of
the study team post visit. All participants had clear and
accurate recollection of personal genetic and cardiac find-
ings from their SCARFE visit.
Secondary findings in inherited heart conditions: a genotype-first feasibility study to assess. . . 1491
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Risk perception
With one exception, participants did not consider, prior to
attending the study visit, that they would have an ICC. This
low perception of risk was informed variously by lack of
symptoms, fitness levels or regular well-person checks in
primary care with no heart problems noted. One participant
perceived his risk as high: he appreciated that he could be
genetically affected but clinically unaffected (earlier tests
showed no signs of HCM). Another participant stated in
hindsight (during interview) that she had expected to ‘have
it’ and this was in some way entwined in her thoughts about
her deceased child, albeit whose condition was unrelated to
ICC:
‘I thought I had it…I didn’t think, oh my God I’m
going to die or anything like that. I just thought, oh
this is linked, perhaps, to [child]. I know [child] was
so complex, so it was just, oh I thought, oh well
perhaps we can help that area as well’. (B3)
However, her very active lifestyle, wellness and parents’
longevity were, for her, in contradiction with the possibility
that she might have an ICC.
Personal consequences of participation
No participant regretted participation in SCARFE. For the
one participant who found to have clinical signs of ICC, the
finding provoked anxiety about the risk posed to continuing
his occupation—a source of satisfaction, financial security
and fulfilment of ambition since childhood—and period of
uncertainty, while he underwent further assessment man-
dated by his employer. Having cleared this process by the
time of interview, his concerns were then about the risk of
HCM to his children, already burdened by significant ill-
ness. The other case participant with a pathogenic variant
(clinically unaffected) found it hard to conceptualise her
risk:
‘Am I lucky to be here? How come something didn’t
happen?..it’s made me wary that I mustn’t go over the
limit..so yes, it’s quite difficult that side’. (B3)
In two control participants, there were unexpected clin-
ical findings unrelated to the ICC. One participant was
found to have a subtly abnormal ECG, which the study team
reported to his primary care doctor; he described subsequent
potential cardiac symptoms on exercise and further medical
investigation and monitoring. A further control participant
believed she had suffered a ‘heart attack’ decades earlier. At
her study visit, she was reassured that her heart showed no
evidence of damage, and this evoked several reactions:
‘Then to find out that all those years when I couldn’t
do things there was nothing wrong with my heart. A
bit angry as well, because it did affect my life a lot… I
go from being relieved—well, I am relieved, I’m very
pleased about my heart’. (B22)
Other participants also recalled relief at learning their
hearts were healthy, but only one (a case) described making
positive lifestyle changes as a result of the study, wishing to
maintain her health. One participant had ‘good intentions’,
others felt they already had a healthy lifestyle.
Family communication and outcomes
The four case participants were advised to inform immediate
relatives and were provided with cascade letters. While all four
had informed relatives, they had not always found it straight-
forward depending on individual relatives’ personalities, cir-
cumstances and family dynamics. One participant with an
elderly parent described her reasons for not informing them;
another had arranged genetic testing with the parent’s care
home. One participant knew of aunts and uncles who, with their
descendants, could be at risk, but had no contact with them.
Responses of heath care system
Aside from SCARFE, participants in general reported per-
sonal experience of strains on primary care practice. Rela-
tives were distributed around the country. In two families,
at-risk relatives had accessed appropriate testing/screening
if they had sought it, but in two, relatives had struggled to
persuade primary care physicians to refer for evaluation:
‘[Relative’s primary care doctor] was not helpful at
all, no. She rang them up and sorted that out for
herself. [Another relative’s doctor] wouldn’t refer
him. He said he would do a blood test for him, but if
he found that he’d got anything, he still wouldn’t refer
him’. (B20)
Other relatives were told they would have to wait many
months for an appointment. One relative had been able to
access cardiac screening but not genetic testing. Primary
care doctors were perceived as having limited under-
standing of genetic risk; this, and delays to appointments,
had caused frustration and sometimes anxiety for partici-
pants and, reportedly, for relatives.
Discussion
To our knowledge, this is the first study reporting on a
systematic approach to disclosure of SF ICC, with targeted
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but genotype-blinded clinical evaluation and detailed
exploration of sequelae of disclosure. Using this approach
we have been able to explore many elements of a policy to
look for and report ICC SF, critical for informing policy
around SF. The possibility that SF might cause high levels
of anxiety has been a concern among healthcare profes-
sionals and publics [19]. Distress or anxiety following SF
disclosure should be factored into the risk/benefit equation,
particularly if SF prove to have relatively low penetrance in
unselected populations. Several studies [28–31], including
one involving LQTS findings [32], have shown that this
concern may be unfounded; but case reports show how
anxiety may lead to disengagement with healthcare services
[16]. Failure to assimilate SF information for whatever
reason might also impede realisation of clinical utility:
‘patients’ (SF recipients) need to make cognitive and
emotional adjustments to health risk information to enable
relevant decisions about their own healthcare and lifestyle,
and communicate risk information successfully to relatives
[33]. Participants in our study denied ongoing anxiety
caused by the SF per se, and were able to act as recom-
mended, attending for further clinical testing and informing
relatives. However, we cannot discount the possibility that
among those who declined participation were some who
might have found adaptation to new risk information chal-
lenging. Participants also demonstrated clear understanding
of genetic health risks and concepts such as variable
penetrance, informed by their experiences with rare disease;
they valued information provided as part of the study design
and the availability of continued access to the study team
after the study visit.
Maximising the clinical utility of SF requires that
healthcare services are able to enact appropriate clinical
follow-up and cascade testing [34]. Unless carriers and
their relatives are able to access genetic testing, clinical
evaluation and follow-up, a search and disclosure policy for
SF is of limited utility. In the present study, we found
variable primary care responses to relatives’ request for a
referral even when supported by a clinical cascade letter:
long waiting times and for one participant, a cardiology
assessment offered before a genetic appointment. While
variability is also seen in ICC clinical practice in the UK,
healthcare professional engagement challenges may be
exacerbated in families in which no one is clinically
affected by the condition associated with the SF. Greater
education and resourcing of primary care physicians may be
required for this aspect of preventative medicine.
In this study, risk perception was low for all participants
who had no family history of ICC. Risk perception was
informed by lack of symptoms and high current or former
levels of activity, as we have observed in an earlier study of
pre-symptomatic testing in ICC [35]. These factors, as well
as general health checks in primary care mentioned by
some, do not preclude clinical signs of ICC. Further
research is needed to understand interactions between risk
perception and outcomes of SF disclosure.
The study identified one variant carrier with HCM, who
had been previously clinically assessed after a diagnosis of
HCM in a first-degree relative, and discharged. Had genetic
testing been used in the proband and in family evaluation, it
is likely the variant would have been detected and the
participant identified as a carrier warranting periodic reas-
sessment. This example highlights the value of clinical
genetic testing and cascading for identifying ICC risk in
relatives, for their personal health and risk assessment of
employees in regulated professions. Incomplete utilisation
of clinical genetic testing in cardiomyopathy (DCM) was
also found in a genetics-first EMR-based study [36].
Genetic testing is a Class 1 recommendation for most ICC
in a proband with clinical suspicion of disease [37]. How-
ever, where genetic testing is either not available or not
informative, a single clinical evaluation of relatives in
young/mid adulthood is insufficient to rule out risk of ICC.
A second carrier of a pathogenic (HCM) variant was
clinically unaffected; cascade testing has clarified that her
surviving parent and that parent’s many descendants are at
population risk. The variant in question, a frameshift in
MYBPC3, is considered unambiguously pathogenic,
occurring at high frequency in the Dutch HCM population
[25] and OMGL. Clearly it is possible that SF disclosure
will fail to find evidence of disease in a family, although we
cannot establish whether the deceased parent’s relatives
have or are at risk of HCM, due to loss of contact with their
descendants.
The study highlights challenges with variant assessment:
the MYL3 variant (c.170C > G p.Ala57Gly) detected in our
study was considered a pathogenic SF by Natajaran et al.
[12] prior to reclassification. Variant interpretation remains
inexact and subject to change, presenting a particular
challenge in the context of SF when the pretest probability
of disease is low [38]; expert laboratory input and genetic
counselling will be critical to ensure patient understanding
and appropriate clinical follow-up. Conversely, a variant
considered a VUS at analysis but subsequently reclassified
as pathogenic would not be disclosed.
A dilemma with recall-by-genotype studies is how to
approach variant carriers to participate without divulging
significant but unexpected risk information or compromis-
ing their right not-to-know [20]. This is a concern for stu-
dies in which participants had not originally consented to
return of SF. Our study design used two strategies to recall
participants: a two-step approach as proposed by Beskow
et al. [21], whereby an initial letter asked participants in the
original study to opt out if they did not wish to learn health
or genetic information additional to what they already knew
about. Two BRRD participants opted out at this stage,
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suggesting that this approach promoted autonomy for some,
however, most who accepted participation were unable to
recall this letter as distinct from the study invitation letter.
Second, we used a case/control strategy, in which partici-
pants could learn more about the study and possible
implications with specialist genetic counselling, before
deciding whether to proceed with clinical screening or
learning their genetic status. While this strategy achieved its
aim, it may have contributed to low recruitment rate. Fur-
ther research is necessary to understand optimal approach in
recall-by-genotype studies.
Study limitations
The main limitation is the small number of eligible partici-
pants and low response rate. From a cohort of over 7000
participants, we are unable to draw conclusions about ICC
penetrance in the general population; given the rarity of
pathogenic variants in these genes, meaningful estimates of
ICC SF penetrance will require a very large sequenced
population together with detailed cardiac phenotyping. While
we have little information about individual reasons for
declining, from participant interviews we can infer factors
that may have contributed to low participation rate: study
participants were recruited from a study investigating rare
disease; many have experienced a high burden of disease,
requiring high levels of care and multiple hospital appoint-
ments. This may have influenced participation rate, psycho-
social and behavioural responses compared with a ‘healthy’
population. In addition, the case-control approach, while
chosen for optimal design as well as to protect participants,
restricted promotion of the possible health benefits of parti-
cipation. In this study, many people chose not to pursue SF,
however, interest in taking part in a research study may not
be comparable with uptake of SF in other contexts.
In conclusion, we have piloted a protocol for return and
clinical evaluation of putatively pathogenic ICC variants as
SF to participants in a study where participants had not been
asked to consent for SF. We show that ICC SF can be
returned and acted upon without undue anxiety in reci-
pients, but that UK clinical healthcare services are not fully
utilising genetic testing in the context of ICC diagnosis, and
may need additional resourcing and education to enact
family cascading following SF disclosure. The finding of an
unambiguously pathogenic ICC SF in a healthy participant
highlights that ICC SF cannot be considered deterministic.
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